深圳奥祺生物科技有限公司成立于 2018 年，是一家充满生命力的制药公司，专业从事战略规划、产品投资和项目管理。凭借全球视野，我们致力于在全球范围内发现和采购有价值的医疗资源，旨在为有需要的人提供高质量的药物。

Founded in 2018, Shenzhen Aoqi Biopharmaceutical is a dynamic pharmaceutical company specialised in strategic planning, product investment and project management. With a global vision, we identify and source valuable medical resources worldwide to deliver quality medicines to people in need.

我们擅长项目评估、技术评估、项目管理和市场拓展。多年来，我们与印度、日本、中国台湾、德国、意大利和波兰的领先制药公司建立了强有力的合作伙伴关系。

We are specialised in project evaluation, technology assessment, project management and market expansion. Over the years we have built strong partnerships with leading pharmaceutical companies in India, Japan, Taiwan China, Germany, Italy and Poland.

我们的核心重点是将优质药物引入中国制药市场并获得许可。产品组合包括口服固体制剂、复杂的液体制剂和体外诊断解决方案。目前已有十余个产品上市销售，自主在研项目 8 项，客户委托研究项目 5 项。

Our core focus is bringing quality medicines into the China pharmaceutical market under license. Our portfolio spans oral solid dosage forms, complex liquid formulations and in-vitro diagnostic solutions. Today we have more than ten marketed products, 8 in-house pipeline projects and 5 client-commissioned research projects.

2022 年我们启动了未来之星孵化业务，筛选国内 CGT 方向的早研项目进行孵化，提供 S&E、IP、BD、FA、PM 等系列专业服务，为这些项目寻找国内外的研发及商业合作机会，并提供融资服务，推动有技术先进性的项目快速转化。

In 2022 we launched the Future Star incubation programme, scouting early-stage CGT projects in China and providing S&E, IP, BD, FA and PM services — connecting them with R&D and commercial partners at home and abroad, and supporting fundraising to accelerate translation of technology-advanced projects.